Search

Mark Awad, MD, PhD, has been appointed Chief of the Thoracic Oncology Service within the Solid Tumor Oncology Division, Department of Medicine at Memorial Sloan Kettering Cancer Center (MSK).

… Friday, September 6, 2024 Mark Awad, MD, PhD , has been appointed Chief of the Thoracic Oncology Service within the Solid Tumor Oncology Division, Department of Medicine at Memorial Sloan Kettering Cancer Center (MSK). Dr. Awad previously served as an Associate Professor at Harvard Medical School and

Memorial Sloan Kettering Cancer Center has announced the gift of a membership interest in Geoffrey Beene, LLC, the company that controls the business and fashion empire created by legendary designer Geoffrey Beene.

… Thursday, October 9, 2008 Memorial Sloan Kettering Cancer Center has announced the gift of a membership interest in Geoffrey Beene, LLC, the company that controls the business and fashion empire created by legendary designer Geoffrey Beene. Revenues generated by Memorial Sloan Kettering’s share in the

A lifelong smoker overcomes discomfort over what a lung cancer imaging test might reveal. She hopes her experience helps reduce the stigma for others who smoke.

… Thursday, September 19, 2024 Marylou Capes-Platt knew she was at an especially high risk for lung cancer . She had been a heavy smoker for 45 years, starting in her teens and continuing through a decades-long career in the music industry and as a writer and editor. She finally quit in 2007. But the threat

Research suggests that a new drug could be effective in patients with prostate cancer who develop resistance to the targeted therapy enzalutamide.

… Tuesday, April 30, 2013 Summary Research suggests that a new drug could be effective in patients with prostate cancer who develop resistance to the targeted therapy enzalutamide. Targeted therapies hold promise for the treatment of many types of cancer. But a common predicament is that in many patients

Learn why post-doctoral researcher Mijin Kim believes Memorial Sloan Kettering is an excellent choice for early career biomedical researchers, as she enjoys her recognition as a STAT Wunderkind, class of 2023.

… Tuesday, October 17, 2023 Mijin Kim, PhD, a postdoctoral researcher at Memorial Sloan Kettering Cancer Center (MSK), has been recognized with the prestigious  Wunderkind award by STAT , the well-regarded news site covering science and medicine. Each year, STAT seeks to find “the best researchers in health

Memorial Sloan Kettering Cancer Center (MSK) researchers presented breakthrough findings for new treatment approaches in several cancer indications at the European Society for Medical Oncology (ESMO) Congress 2022, held September 9 to 13 in Paris. Highlights included clinically meaningful benefits for new treatment strategies in advanced bladder cancer, endometrial cancer, and renal cell carcinoma. Additionally, MSK experts shared their perspectives on previously reported groundbreaking trials of new treatment approaches in colorectal cancer and HER2-low metastatic breast cancer.

… Tuesday, October 11, 2022 Advanced Bladder Cancer: Promising Results for Enfortumab Vedotin Plus Pembrolizumab MSK has been spearheading the development and testing of antibody-drug conjugates — novel biopharmaceuticals that deliver precise payloads of anti-cancer agents directly to cancer cells — alone

During a virtual awards ceremony, MSK and the Robbins Family Foundation recognized eight distinguished MSK staff members and one team for their exemplary service. Each member was honored with the 2021 Robbins Family Award for Nursing Excellence.

… Wednesday, May 12, 2021 Elizabeth McCormick, Senior Vice President, and Chief Nursing Executive Elizabeth McCormick, Senior Vice President, and Chief Nursing Executive MSK Nurses celebrate Nurses Week, May 6-12 MSK Nurses celebrate Nurses Week, May 6-12 MSK Nurses celebrate Nurses Week, May 6-12 MSK

Memorial Sloan Kettering Cancer Center (MSK) today announced that it has been awarded a Specialized Programs of Research Excellence (SPORE) grant for pancreatic research by the National Cancer Institute (NCI).

… Tuesday, October 11, 2022 Memorial Sloan Kettering Cancer Center (MSK) today announced that it has been awarded a Specialized Programs of Research Excellence (SPORE) grant for pancreatic research by the  National Cancer Institute (NCI) . The long-term goal of the grant is to demonstrate that prospective

Memorial Sloan Kettering’s 37th annual academic Convocation and the fifth Louis V. Gerstner Graduate School of Biomedical Sciences Commencement shared the spotlight on May 19.

… Tuesday, July 5, 2016 An afternoon ceremony on May 19 celebrated MSK’s 37th annual Convocation and the fifth Louis V. Gerstner Graduate School of Biomedical Sciences Commencement. Presided over by MSK President and CEO Craig Thompson , it recognized students who conducted their doctoral dissertation

Memorial Sloan Kettering Cancer Center (MSK), The Rockefeller University and Weill Cornell Medicine announced today that they have established a new drug discovery company called Bridge Medicines. Launched in partnership with Takeda Pharmaceutical Company Ltd. and healthcare investment firms Bay City Capital and Deerfield Management, Bridge Medicines is a groundbreaking initiative that completes a seamless, fully funded and professionally staffed path from concept to drug candidate to efficiently and rapidly develop innovative therapeutics for treating human diseases.

… Monday, October 31, 2016 Memorial Sloan Kettering Cancer Center, The Rockefeller University and Weill Cornell Medicine announced today that they have established a new drug discovery company called Bridge Medicines. Launched in partnership with Takeda Pharmaceutical Company Ltd. and healthcare investment